Issue 43 - Nov 15, 2019
Issue 42 - Nov 8, 2019
Issue 41 - Nov 1, 2019
  • An Appreciation

    When Bernie Fisher refused to grovel

    Bernard Fisher had been in many a fight. He was, after all, an iconoclastic surgeon who had famously infuriated his colleagues by demonstrating that heroic surgeries in breast cancer do more harm than good.

  • Anatomy of a Scandal

    On a single day in March, Dr. Bernard Fisher of Pittsburgh, the country’s pre-eminent breast cancer researcher, saw his own career crumble, and watched helplessly as the research organization he had led through unprecedented advances in the treatment of breast cancer was abruptly shut down.

  • Added indignity: NIH labels Fisher’s papers as “SCIENTIFIC MISCONDUCT”

    The midterm elections of 1994 brought on political change that cost Dingell chairmanship of Energy & Commerce and Oversight and Investigations. He lost most of his staff, and there was no reason to continue oversight hearings of NSABP.

  • Breaking News

    Sharpless to return to NCI as Hahn gets nominated as FDA commissioner, with Giroir to serve as acting

    President Donald Trump has announced his intention to nominate Stephen M. Hahn to the position of FDA commissioner Nov. 1.

  • In Brief

    • Robert Winn named director of VCU Massey Cancer Center
    • Myles Brown, Celina Kleer to receive awards at San Antonio Breast Cancer Symposium
    • Brian Rini joins Vanderbilt-Ingram as chief of clinical trials
    • NCI awards UCLA prostate cancer SPORE $8.7M
    • Johns Hopkins opens proton center at Sibley Memorial Hospital
    • Allyson Kinzel named senior vice president and chief legal officer at MD Anderson
    • James Kochenderfer receives Foundation for the NIH Awards 2019 Trailblazer Prize
    • Astellas awards $200,000 in cancer grants
  • TCCL Logo

  • Clinical Roundup

    • Study finds racial disparities in treatment of multiple myeloma patients
    • Dana-Farber and UT Southwestern study finds racial disparities in culturally competent cancer care
    • NCCN publishes guidelines on managing complications and improve readiness for stem cell transplants
    • Acute lymphoblastic leukemia relapses reduced by 31%, St. Jude study shows
  • Drugs & Targets

    • AACR Project GENIE begins five-year research project with $36M in industry funding
    • European Commission approves Astellas’ Xospata indication for relapsed or refractory AML
    • DA grants Cytotron Breakthrough Device Designation for breast, liver and pancreatic cancers
    • MD Anderson, Ziopharm Oncology to expand TCR-T Program